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Abstract
Purpose To determine the value of 68Ga-DOTA-TOC and
18F-FDG PET/CT for initial and follow-up evaluation of pa-
tients with neuroendocrine tumour (NET) treated with peptide
receptor radionuclide therapy (PRRT).
Methods We evaluated 66 patients who had histologically
proven NET and underwent both PRRT and three combined
68Ga-DOTA-TOC and 18F-FDG PET/CT studies. 68Ga-
DOTA-TOC PET/CTwas performed before PRRT, 3 months
after completion of PRRT and after a further 6 – 9 months.
18F-FDG PET/CTwas done within 2 months of 68Ga-DOTA-
TOC PET/CT. Follow-up ranged from 11.8 to 80.0 months
(mean 34.5 months).
Results All patients were 68Ga-DOTA-TOC PET-positive ini-
tially and at follow-up after the first full PRRT cycle. Overall,
62 of the 198 18F-FDG PET studies (31 %) were true-positive
in 38 of the 66 patients (58 %). Of the 66 patients, 28 (5 grade
1, 23 grade 2) were 18F-FDG-negative initially and during
follow-up (group 1), 24 (5 grade 1, 13 grade 2, 6 grade 3)
were 18F-FDG-positive initially and during follow-up (group
2), 9 patients (2 grade 1, 6 grade 2, 1 grade 3) were 18F-FDG-
negative initially but 18F-FDG-positive during follow-up
(group 3), and 5 patients (all grade 2) were 18F-FDG-positive
initially but 18F-FDG-negative during follow-up (group
4).18F-FDG PET showed more and/or larger metastases than
68Ga-DOTA-TOC PET in five patients of group 2 and four
patients of group 3, all with progressive disease. In three pa-
tients with progressive disease who died during follow-up
tumour SUVmax increased by 41 – 82 % from the first to
the last follow-up investigation.
Conclusion In NET patients, the presence of 18F-FDG-posi-
tive tumours correlates strongly with a higher risk of progres-
sion. Initially, patients with 18F-FDG-negative NET may
show 18F-FDG-positive tumours during follow-up. Also pa-
tients with grade 1 and grade 2 NET may have 18F-FDG-
positive tumours. Therefore, 18F-FDG PET/CT is a comple-
mentary tool to 68Ga-DOTA-TOC PET/CTwith clinical rele-
vance for molecular investigation.
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Introduction
Neuroendocrine tumours (NET) are a heterogeneous group of
neoplasms characterized by their overexpression of somato-
statin receptors (SSTR) on the cell surface [1]. Several studies
have demonstrated the effectiveness of SSTR-targeted imag-
ing for diagnosis, staging, follow-up and deciding upon the
suitability of peptide receptor radionuclide therapy (PRRT)
[2–5]. The standard indication for PRRT with the
radiolabelled SSTR analogues 177Lu/90Y-labelled DOTA-
Tyr3-octreotide (TOC)/TATE/lanreotide is metastatic and in-
operable SSTR-positive NET, evaluated by SSTR imaging
with 68Ga-DOTA-TOC/TATE/NOC/lanreotide PET/CT or
99mTc-HYNIC-TOC/111In-DOTA-TOC/lanreotide scintigra-
phy, among others [6–10]. The former approach is preferable
because of its superior resolution and hence better sensitivity
than that of conventional scintigraphy. PET/CT imaging has
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also been shown to be superior to conventional imaging (CT,
MRI) for staging [2, 3, 11].
NET typically have a wide range of cellular differentiation.
WHO guidelines classify NET into three grades based on cell
proliferation, the number of mitoses and the expression of the
nuclear antigen Ki-67. Gastroenteropancreatic NET are clas-
sified as low grade (grade 1, Ki-67 <2 %), intermediate grade
(grade 2, Ki-67 3 – 20 %) and high grade (grade 3, Ki-67
>20 %) [12]. Both proliferation index and grade strongly cor-
relate with tumour behaviour and prognosis [10, 13,
14]. High-grade, poorly differentiated NET often have
limited expression of SSTR [10], what can lead to
false-negative SSTR imaging results and make the mo-
lecular investigation difficult.
18F-FDG PET/CT is used to assess glycolytic metabolism,
and higher uptake of 18F-FDG has been found to be associated
with tumour aggressiveness [15]. 18F-FDG PET/CT has thus
been used increasingly in the recent years for the evaluation of
high-grade NET [15, 16]. To date, however, only a few studies
have investigated the correlation between 18F-FDG and SSTR
imaging and NET grade. A dichotomous behaviour has been
found between these approaches in well-differentiated and
poorly differentiated NET, where the former was more posi-
tive on SSTR imaging [16, 17] and the latter on 18F-FDG PET
[18–20]. Hence, adopting a dual-tracer approach
encompassing SSTR and 18F-FDG PET imaging, assessing
SSTR expression and glycolytic metabolism, respectively,
could support better individualization of therapy selection in
patients with NET. High 18F-FDG uptake would suggest an
aggressive behaviour and the possibility of treatment refracto-
riness of the cells at the site, whereas low uptake would indi-
cate a biologically indolent lesion.
We performed an intrapatient comparison of the results of
68Ga-DOTA-TOC and 18F-FDG PET/CT in the initial and
follow-up evaluation of NET patients who had received the
first full treatment cycle with PRRT.We also evaluated wheth-




We retrospectively evaluated a cohort of 66 patients with his-
tological confirmation of NET (according to the ENETS
criteria) [13] who underwent PRRT (after confirmation of
SSTR-positive lesions with 68Ga-DOTA-TOC PET/CT) and
underwent three combined studies with 68Ga-DOTA-TOC
and 18F-FDG PET/CT at our institution between 2005 and
2013. The methods of tissue collection were resection of the
primary tumour in 27 patients, surgical excision of a metasta-
tic lesion in 3 patients and biopsy of a metastatic lesion in the
other 36 patients. The Ki-67 index was evaluated with immu-
nohistochemistry. Patient demographics are shown in Table 1.
All patients included in the study were in advanced stages
requiring systemic antitumour therapy in a palliative setting.
In particular, more than 65 % had metastases in more than one
location, and most of them showed widespread metastases.
Before undergoing PRRT, 43 patients were treated with other
modalities including resection of the primary tumour (27 pa-
tients), chemotherapy (7 patients), and radiofrequency abla-
tion or embolization of liver metastases (9 patients). The re-
maining 23 patients with widespread metastases were referred
to our department for PRRT without previous therapy. Three
patients were syndromic (two with insulinoma, one with
gastrinoma). Fifteen patients had tumour progression at study
entry. The average time from initial diagnosis to PRRT was
3.8 years (range 1 – 11 years, standard deviation ±1.4 years).
Table 1 Demographic data
Characteristic Value
Total number of patients 66
Age at initial diagnosis (years)
Mean ± standard deviation 57.2 ± 7.0


























The data presented are number of patients, except age in years
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68Ga-DOTA-TOC PET/CTwas performed at baseline (i.e.
before PRRT), 3 months after completion of the first full
PRRT cycle and every 6 – 9 months thereafter. All patients
proceeding to PRRT underwent a 18F-FDG PET/CT scan as
part of routine work-up. 68Ga-DOTA-TOC and 18F-FDG
PET/CT were performed within 2 months of each other.
Between these two scans no PRRTwas given. A total of 198
combined 68Ga-DOTA-TOC and 18F-FDG PET/CT studies
(baseline and after the first PRRT) were evaluated. Follow-
up ranged from 11.8 to 80.0 months (mean 34.5 months).
Peptide receptor radionuclide therapy
90Y-DOTA-TOC was used as the radiopharmaceutical of first
choice for PRRT. 177Lu-DOTA-TATE was used if tumour le-
sions were smaller than 2 cm in diameter or in patients under-
going retreatment. 90Y-DOTA-TOC and 177Lu-DOTA-TATE
were administered intravenously.
The periods between baseline evaluation and the first
PRRT administration, and between RECIST 1.1 assessment
and PRRT administration were <4 weeks. Three to four ther-
apy cycles with 3.7 GBq 90Y-DOTA-TOC or 7.4 GBq 177Lu-
DOTA-TATE were administered at an interval of 10 – 14
weeks. The treatment protocol used in our department [6]
included the additional administration of Bcold^ long-acting
SST analogues. These were administered after PRRT and re-
peated 4 weeks later. Retreatment with PRRT was performed
at least 6 weeks after the use of Bcold^ long-acting SST
analogues.
In 23 patients treatment was solely with 90Y-DOTA-TOC,
in 22 patients solely with 177Lu-DOTA-TATE and in 21 pa-
tients with both agents sequentially. Thirty-five patients were
retreated with PRRT. The number of therapy cycles with 90Y-
DOTA-TOC ranged from 4 to 11 (cumulative activity
10.6 – 27 GBq) and with 177Lu-DOTA-TATE ranged from 4
to 9 (cumulative activity 16.3 – 37.5 GBq).
Positron emission tomography
68Ga-DOTA-TOC
Preparation of 68Ga-DOTA-TOC was based on a fully auto-
mated synthesis, as described previously [21]. The patients
received 100 – 150 MBq of 68Ga-DOTA-TOC (20 – 30 μg)
intravenously. The radiation exposure related to 68Ga-DOTA-
TOC was 2.3 – 3.45 mSv [22]. PET acquisition was started
60 – 90 min (median 75 min) after injection. Imaging was
performed with a dedicated PET scanner (MS-Advance or
MS-Discovery 450; GE Healthcare). Images were acquired
from the head to the mid-thigh. Attenuation correction was
performed using transmission data obtained with a 67Ge pin
source at 3 min per bed position (MS-Advance) or a CT scan
(MS-Discovery 450). Ordered-subsets expectation maximiza-
tion was used for image reconstruction.
18F-FDG
Patients received 200 – 300 MBq of 18F-FDG intravenously
after fasting for at least 8 hours. The radiation exposure related
to 18F-FDG was 2.4 – 3.6 mSv [23]. PET acquisition was
started 52 – 80 min (median 65 min) after injection. The set-
tings and protocol were as described for 68Ga-DOTA-TOC.
CT
A 2.5-mm helical CT scan was performed on a HiSpeed CT/I
Advantage scanner (GE Healthcare). Approximately 1.5 mL/
kg body weight of Visipaque 320 contrast medium (GE
Healthcare) was administered. The radiation exposure related
to CT was 2 – 12 mSv [24].
Image review
68Ga-DOTA-TOC and 18F-FDG PET images were assessed
by two experienced board-certified nuclear medicine physi-
cians. Criteria for a positive finding on PETstudies were focal
area(s) of increased tracer uptake or diffusely increased up-
take, excluding physiological uptake, in comparison with ad-
jacent tissue on axial, coronal and sagittal images. When the
PET results corresponded with those of conventional imaging
or histopathology, or when a corresponding lesion appeared
on conventional imaging during follow-up, the PET results
were rated as true-positive. Lesions not detected on PET but
seen on conventional imaging and showing progression dur-
ing follow-up or confirmed by histopathology were rated as
false-negative. PET results suggestive of tumour lesions with-
out corresponding lesions found on conventional imaging dur-
ing follow-up or verification by histopathology were rated as
false-positive.
All PET/CT images were analysed using commercially
available software (eNTEGRA; GE Healthcare), which
allowed review of PET, CT and fused imaging data.
Semiquantitative analysis of all pathological lesions on 18F-
FDG PET, calculating the maximum standardized uptake val-
ue (SUVmax), was performed. For calculation of the SUV,
regions of interest were drawn around areas with focally in-
creased uptake on transaxial slices and automatically adapted
to a 3-D volume of interest at a 70 % isocontour. The lesion
with the highest SUVmax was chosen for data analysis. No
SUVmax cut-off value was applied to differentiate benign from
malignant lesions.
RECIST 1.1 was used for determining tumour response to
treatment. Based on all imaging and histological findings as
appropriated, tumour response was categorized as complete
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response (CR), partial remission (PR), stable disease (SD) or
progressive disease (PD) [25, 26].
Statistical analysis
SPSS software (version 18.0 for Windows SPSS Inc.,
Chicago, IL, and LEAD Technologies, Charlotte, NC) was
used for statistical evaluation of the results. Continuous vari-
ables are expressed as mean values with standard deviations.
The chi-squared test and t test were used. A p value <0.05 was
considered statistically significant.
Results
The disease course at last follow-up was CR in 3 patients
(4.5 %), PR in 4 (6.1 %), SD in 35 (53.0 %) and PD in 24
(36.4 %). Figure 1 shows the disease course according to
primary site.Figure 2 shows the influence of the primary tu-
mour on disease course.
68Ga-DOTA-TOC PET
All patients showed SSTR-positive tumour lesions at baseline
and follow-up after the first full PRRT cycle. 68Ga-DOTA-
TOC-positive lesions were primary tumours in 17 patients
(25.8 %; pancreas in 12, lung in 4, ileum in 1 patient) and
metastatic sites in 65 patients (98.5 %; liver in 63, lymph node
in 32, bone in 23, lung in 8, brain in 1, adrenal gland in 1
patient).
18F-FDG PET
Overall, 62 of the 198 18F-FDG PET/CT studies (31.3 %)
were true-positive in 38 of the 66 patients (57.6 %). Two other
patients showed 18F-FDG-positive lesions (lymph nodes in 2
patients, lung in 1 patient) only once during follow-up without
correlating lesions on 68Ga-DOTA-TOC PET/CT and that
were not seen on further follow-up investigations even though
no therapeutic intervention took place. These two 18F-FDG
PET/CT investigations were rated as false-positive.
Analysis on a per-patient basis
Patients were classified into four groups according to the 18F-
FDG PET results as defined in the following sections. The
18F-FDG PET findings and disease course in each patient
group are shown in Fig. 3.
Group 1 Patients 18F-FDG-negative initially and during
follow-up (28 patients, 42.4 %)
68Ga-DOTA-TOC was positive in 2 primary tumours (2
patients) and in 52 metastatic sites (28 patients; Fig. 4).The
tumour was grade 1 in 5 patients and grade 2 in 23 patients.
Group 2 Patients 18F-FDG-positive initially and during
follow-up (24 patients, 36.4 %)
Fig. 1 Disease course according to primary site (CR complete response,
PR partial remission, SD stable disease, PD progressive disease)
*p< 0.05 as compared with SD and PR;Δ p < 0.05 as compared with PD
Fig. 2 Influence of the primary tumour on disease course (CR complete
response, PR partial remission, SD stable disease, PD progressive disease)
*p<0.05 as compared with group of inoperable or unknown primaries
Fig. 3 18F-FDG PET findings and disease course in each patient group:
Group 1 patients 18F-FDG-negative initially and during follow-up;Group
2 patients 18F-FDG-positive initially and during follow-up; Group 3 pa-
tients 18F-FDG-negative initially, but 18F-FDG-positive during follow-
up; Group 4 patients 18F-FDG-positive initially, but 18F-FDG-negative
during follow-up (CR complete response, PR partial remission, SD stable
disease, PD progressive disease; *p < 0.05 as compared with group 2
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18F-FDG PET was positive in 8 primary tumours (8 pa-
tients) and 44 metastatic sites (24 patients; Fig. 5). 18F-FDG
PET showed more and/or larger metastases than 68Ga-DOTA-
TOC PET in 5 patients (all with PD during follow-up). A ‘flip/
flop’ phenomenon (with negative 18F-FDG PET but positive
68Ga-DOTA-TOC PET in some lesions, and positive 18F-
FDG PET but negative 68Ga-DOTA-TOC PET in other le-
sions) was seen in 2 patients with PD.
68Ga-DOTA-TOC PET was positive in 9 primary tumours
(9 patients) and 55 metastatic sites (24 patients). 68Ga-DOTA-
TOC PET showed more metastases than 18F-FDG PET in 11
patients (3 patients with SD and 8 patients with PD during
follow-up).
The tumour was grade 1 in 5 patients, grade 2 in 13 patients
and grade 3 in 6 patients. Five patients died during follow-up
(SD in 1 patient with grade 1, PD in 1 patient with grade 1, 2
patients with grade 2 and 1 patient with grade 3 tumour).
Group 3 Patients 18F-FDG-negative initially but 18F-
FDG-positive during follow-up (9 patients,
13.6 %)
18F-FDG PET was positive in 3 primary tumours (3 pa-
tients) and 12 metastatic sites (9 patients; Fig. 6). 18F-FDG
68Ga-DOTA-TOC PET/CT 18F-FDG PET/CT
  Initial evaluation 
Follow-up 
Fig. 4 A 75-year-old male patient with grade 1 NET in the ileum.
Positive 68Ga-DOTA-TOC PET (progressive disease) and negative
18F-FDG PET initially and during follow-up
68Ga-DOTA-TOC PET/CT 18F-FDG PET/CT
  Initial evaluation 
Follow-up 
Fig. 5 A 32-year-old male patient with grade 2 NET in the pancreatic
tail. Positive 68Ga-DOTA-TOC PET and 18F-FDG PET initially and dur-
ing follow-up (progressive disease)
68Ga-DOTA-TOC PET/CT 18F-FDG PET/CT
  Initial evaluation 
Follow-up 
Fig. 6 A 59-year-old female patient with grade 2 NET in the pancreatic
head. Positive 68Ga-DOTA-TOC PET and negative 18F-FDG PET
initially but positive 18F-FDG-PET/CT during follow-up (progressive
disease)
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PETshowed more and/or larger metastases than 68Ga-DOTA-
TOC PET in 4 patients (all with PD during follow-up).
Positive 68Ga-DOTA-TOC PET was seen in 3 primary tu-
mours (three patients) and 13 metastatic sites (nine patients).
The tumour was grade 1 in two patients, grade 2 in six patients
and grade 3 in one patient.
Group 4 Patients 18F-FDG-positive initially but 18F-
FDG-negative during follow-up (five patients,
7.6 %)
Positive 18F-FDG PETwas found in three primary tumours
(three patients) and eight metastatic sites (five patients).
Positive 68Ga-DOTA-TOC PET was seen in three primary
tumours (three patients) and eight metastatic sites (five pa-
tients). The tumour was grade 2 in all patients. The disease
course was CR in one patient (who was re-treated with PRRT
and had radiofrequency ablation of liver metastases), PR in
one patient (who was re-treated with PRRT; Fig. 7), and SD in




In patients with 18F-FDG-positive lesions the SUVmax ranged
from 3.0 to 13.0. No significant differences in SUVmax were
found among the tumour grades or the various disease course
groups. In patients with a more favourable disease course, the
SUVmax in the primary tumour and metastases remained un-
changed or showed a slight variation (5 % to 13 %) from first
to last follow-up. However, in 3 patients with PD who died
during follow-up, the SUVmax of the primary tumour (1 pa-
tient) and in various metastases (3 patients) showed an in-
crease of 41 % to 82 % from first to last follow-up (SUVmax
ranging from 11.2 to 11.9).
Discussion
In the past few years, SSTR imaging with 68Ga-labelled pep-
tide PET/CT has been shown to provide excellent sensitivity
and specificity for diagnosing and staging NET [2, 3]. 18F-
FDG PET is widely used in oncology, but its use in NET is a
matter of controversy. Initial studies [20, 27], performed in a
small number of patients only, cast doubt on the use of 18F-
FDG PET in NET patients. The loss of SSTR expression was
found to coincide with a gain in glucose utilization in tumours
[28]. Consequently, it was suggested that the use of 18F-FDG
PET be limited to SSTR-negative NET. More recent studies
including a larger number of patients evaluated the
xsensitivity of 18F-FDG PET in NET patients in comparison
with that of 68Ga-DOTA-TATE PET/CT [16] and in relation to
survival [29]. These studies showed that the higher the grade
of NET, the higher is the prevalence of glucose hypermetabol-
ic tumours [16], which have been linked with more aggressive
tumour features including a higher risk of death [29]. This
study confirmed that 18F-FDG positivity is strongly correlated
with a higher risk of progression, in agreement with the find-
ings of Garin et al. [30] showing that 18F-FDG PET has a
prognostic value for early tumour progression. Furthermore,
an important finding of our investigation is the evidence that
patients may develop 18F-FDG-positive lesions during fol-
low-up. This finding supports the value of repeating 18F-
FDG PET in the long-term follow-up of NET patients, in
particular if there are signs of progression on other imaging
methods such as SSTR PET/CT.
Based on the Ki-67 proliferation index which is determined
from analysis of a tumour sample taken mostly at the time of
initial diagnosis, it is possible to stratify patients into different
risk groups. However, a one-time collected parameter might
not have the power to form the basis for therapeutic decisions
at all stages and time-points during the disease course.
Moreover, the collected tumour tissue might not be represen-
tative of all tumour lesions. For appropriate therapy planning
it is important to detect the highest proliferative activity
68Ga-DOTA-TOC PET/CT 18F-FDG PET/CT
  Initial evaluation 
Follow-up 
Fig. 7 A 64-year-old male patient with grade 2 NET in the pancreatic
head. Positive 68Ga-DOTA-TOC PET and 18F-FDG PET initially but
negative 18F-FDG-PET during follow-up (partial remission)
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among all tumour lesions. SSTR imaging and 18F-FDG
PET are modalities for noninvasive visualization of the
whole body.
High 18F-FDG SUVs seem to be strongly correlated with
short survival in NET patients. In accordance with Binderup et
al. [29] who found that patients with a SUVmax higher than 9
are more likely to have a shorter overall survival, in 3 patients
with progression who died during follow-up we found
SUVmax in the range 11.2 to 11.9 in various tumours at the
last follow-up, and importantly the values had increased 41 %
to 82 % from the first follow-up. We did not perform a corre-
lation study between 18F-FDGSUVs and Ki-67 index. Further
prospective ongoing studies are necessary to establish the val-
ue of SUV in NET patients, in particular for assessing survival
and progression-free survival.
The ENETS guidelines recommend that in patients with
fast progression of NET classified as grade 1 or grade 2 a re-
biopsy should be considered, but do not recommend 18F-FDG
PET routinely during follow-up [31]. Guidelines now consid-
er a place for 18F-FDGPET in a patient with grade 2 tumour in
whom liver transplantation is planned to ascertain the absence
of extrahepatic tumour lesions or other malignancies [10]. In
this study, we confirm that patients with grade 1 or grade 2
NET may also have 18F-FDG-positive tumours initially and
may develop 18F-FDG-positive lesions during follow-up.
These findings must be taken into account, especially in indi-
vidualized and optimized therapy planning.
The limitations of this retrospective study were the small
number of patients in the subgroups, due in part to the hetero-
geneity of NETand the tumour primary sites, and the different
treatments performed before and during follow-up. The treat-
ment protocol used in our department included 90Y-DOTA-
TOC as the radiopharmaceutical of first choice for PRRT.
Although the possible superiority of 90Y for larger tumours
has not been shown by direct comparison of 90Y-DOTA-TOC
and 177Lu-DOTA-TATE, the rationale for using 90Y-DOTA-
TOC in patients with tumours larger than 2 cm in diameter
was based on data using a mathematical modelling approach
based on the physical characteristics of therapeutic radionu-
clides [32]. A previous study has indicated that PRRT may
lead to a reduction in glucose metabolism in NET lesions,
depending on the amount of SSTR uptake as demonstrated
by 68Ga-DOTA-NOC PET [9]. We evaluated mainly patients
with grade 1 and grade 2 NET. Therefore, we were not able to
further investigate the behaviour of grade 3 NET during the
course of the disease with regard to 18F-FDG positivity of the
tumour lesions.
In conclusion, our results show that investigation only of
SSTR status by 68Ga-DOTA-TOC PET/CT may not reflect
progression in certain NET lesions. Therefore, the decision
on a change in therapeutic strategy in a patient with a poor
prognosis cannot be based on this one modality alone. Hence,
we recommend performing 18F-FDG PET in the initial
evaluation and during follow-up of NET patients, espe-
cially when SSTR PET/CT shows progression. 18F-FDG
PET/CT is a clinically relevant, complementary tool to
68Ga-DOTA-TOC PET and its use represents a step to-
wards personalized medicine in the management of NET
patients.
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